Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy

Sánchez, Jorge; Álvarez, Leidy; García, Elizabeth

doi:10.2217/imt-2022-0215

Cited by 3 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…221 Asthma patients in the AIT group also had higher rates of complete drug reduction. 222 Additionally, the cost-effectiveness of AIT for allergic asthma, particularly SCIT, has been demonstrated, which may influence future policy decisions and prescribing habits. Even when accounting for allergic rhinitis as a comorbidity, SCIT remained cost-effective.…”

Section: Ait For Allerg I C a S Thmamentioning

confidence: 99%

“…218 The results of the RCTs show asthma symptom control, decrease in exacerbations and medication use are currently confirmed by RWEs. 105,[221][222][223] It has been shown, that HDM-SLIT enhances bronchial epithelial antiviral tolerance against viral infection. These findings could explain why HDM-SLIT is effective at reducing allergic asthma exacerbations.…”

Section: Ait For Allerg I C a S Thmamentioning

confidence: 99%

“…Furthermore, birch pollen AIT has proven its long‐term effectiveness, reducing AR and asthma medication intake up to 6 years post‐treatment 221 . Asthma patients in the AIT group also had higher rates of complete drug reduction 222 . Additionally, the cost‐effectiveness of AIT for allergic asthma, particularly SCIT, has been demonstrated, which may influence future policy decisions and prescribing habits.…”

Section: Ait For Allergic Asthmamentioning

confidence: 99%

See 2 more Smart Citations

Hot topics in allergen immunotherapy, 2023: Current status and future perspective

Zemelka‐Wiacek,

Agache,

Akdis

et al. 2023

Allergy

View full text Add to dashboard Cite

The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.

show abstract

Section: Ait For Allerg I C a S Thmamentioning

confidence: 99%